POSTNEOADJUVANT THERAPY STAGE III GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA AJCC V8
Clinical trials for POSTNEOADJUVANT THERAPY STAGE III GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA AJCC V8 explained in plain language.
Never miss a new study
Get alerted when new POSTNEOADJUVANT THERAPY STAGE III GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA AJCC V8 trials appear
Sign up with your email to follow new studies for POSTNEOADJUVANT THERAPY STAGE III GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA AJCC V8, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New combo drug trial hopes to shrink tough cancers
Disease control Recruiting nowThis early-stage study tests a new combination of two drugs (trifluridine/tipiracil and talazoparib) in people with advanced colorectal or gastroesophageal cancers that have spread. The main goals are to find the safest dose and understand side effects. About 45 participants will…
Matched conditions: POSTNEOADJUVANT THERAPY STAGE III GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA AJCC V8
Phase: PHASE1 • Sponsor: Roswell Park Cancer Institute • Aim: Disease control
Last updated May 15, 2026 11:56 UTC
-
New drug combo shows promise for tough stomach cancers
Disease control Recruiting nowThis early-phase study tests two drugs, pembrolizumab and lenvatinib, in about 15 people with advanced stomach or gastroesophageal cancer that has spread or can't be surgically removed. Pembrolizumab helps the immune system attack cancer cells, while lenvatinib blocks enzymes tha…
Matched conditions: POSTNEOADJUVANT THERAPY STAGE III GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA AJCC V8
Phase: EARLY_PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 04, 2026 16:23 UTC